Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Recurrent infection-induced autoimmune haemolytic anaemia complicated by pulmonary embolism: a case report and literature review

Shu Fang and Fan Yang
Download PDF
DOI: https://doi.org/10.7861/clinmed.2021-0112
Clin Med May 2021
Shu Fang
APeking University First Hospital, Beijing, China
Roles: resident physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fan Yang
BPeking University First Hospital, Beijing, China
Roles: attending physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dryangf@126.com
  • Article
  • Figures & Data
  • Info & Metrics
Loading

ABSTRACT

A 73-year-old woman presented with progressive dyspnoea up to type 1 respiratory failure. Laboratory values showed leucocytosis, reduced haemoglobin to 71 g/L, elevated indirect serum bilirubin and lactic dehydrogenase. Computed tomography pulmonary angiography (CTPA) revealed peripheral pulmonary embolism (PE). Echocardiography showed enlarged right ventricle, elevated estimated pulmonary arterial systolic pressure (57.2 mmHg) and normal left ventricular ejection fraction. The patient was diagnosed with autoimmune haemolytic anaemia (AIHA), which was induced by recurrent infections without standard treatment in the past year. AIHA is the cause of PE due to the absence of common predisposing factors and other thrombophilia. The patient became better after administration of glucocorticoids, intravenous immunoglobulin and rivaroxaban.

KEYWORDS:
  • autoimmune haemolytic anaemia
  • pulmonary embolism
  • infection

Case presentation

A 73-year-old woman was referred to the emergency department (ED) with progressive dyspnoea, weakness and dark urine for about 10 days. She complained of recurrent fever for 1 year due to pneumonia or urinary tract infection (UTI). She presented to local hospital and was diagnosed with suspicious infection due to leucocytosis. Although treating with moxifloxacin, her symptoms failed to relieve. Past medical history included reflux oesophagitis for many years and was treated with omeprazole. She has no history of illicit substance use.

Vital signs were blood pressure at 116/62 mmHg, heart rate of 90 beats/min, respiratory rate of 26 breaths/min and oxygen saturation of 85% on room air. Physical examination showed high-pitched P2, no crackles and rhonchi in both lungs, no peripheral oedema, no erythema and no palpable cords. The initial significant findings revealed type 1 respiratory failure, haemoglobin (Hb) was 71 g/L with white cell count of 23.01 × 109/L, neutrophils of 74.2% and platelet count of 241 × 109/L; a high level of D-dimer (2.78 mg/L); troponin I (cTNI) was 0.091 ng/mL and brain natriuretic peptide (BNP) was 236 pg/mL. A 12-lead electrocardiography (ECG) showed no abnormalities in ST segment and T wave (Fig 1). Emergent computed tomography pulmonary angiography (CTPA) showed bilateral subsegmental and segmental pulmonary emboli (Fig 2a).

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

Electrocardiography on admission.

Fig 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 2.

Comparison of computed tomography pulmonary angiography. a) Image on admission showing bilateral subsegmental and segmental pulmonary embolism. b) Image at 3 months after discharge showing no pulmonary embolism.

Initial management

The patient was sent to the cardiac care unit (CCU). Echocardiography showed enlarged right ventricle and elevated estimated pulmonary arterial systolic pressure (57.2 mmHg) and normal left ventricular ejection fraction (81.2%). Dynamic changes of laboratory results are summarised in supplementary material S1. We exclude common predisposing factors and other thrombophilia for pulmonary embolism (PE) by a detailed history and laboratory test (cardiolipin anti-antibody, anti-β2-glycoprotein 1 antibody, lupus anticoagulant, protein C or S were normal). The patient suffered from haemolytic anaemia as judged by elevated reticulocyte and serum bilirubin. Further tests showed peripheral blood smears, paroxysmal nocturnal haemoglobinuria (PNH) clone, haemoglobin electrophoresis, erythrocyte penetration fragility test, G6PD activity, complement H factor concentration, complement H factor antibody and ADAMTS13 were all normal. Coombs test was positive, and resulted in the diagnosis of autoimmune haemolytic anaemia (AIHA). The works for secondary AIHA included other autoimmune diseases (antinuclear antibody, anti-dsDNA were negative), serum immunofixation electrophoresis (no monoclonal band) and a computed tomography to exclude lymphoma and solid tumours. In addition, T-SPOT.TB, the immunoglobulin M of mycoplasma, Epstein-Barr virus (EBV), cytomegalovirus (CMV), influenza virus, rubella virus, measles, adenovirus and parvovirus B19, hepatitis B surface antigen (HBsAg) and HIV antibodies were all negative. Finally, PE attributed to AIHA was considered due to no common aetiology of PE.

According to guidelines, the patient was stratified as Pulmonary Embolism Severity Index (PESI) class IV, simplified PESI (sPESI) ≥1, the risk of early death is intermediate-high.1 She received low-molecular weight heparin (LMWH) and discontinued other suspicious drugs. During hospitalisation, she once received intravenous methylprednisolone sodium succinate 40 mg once daily (od)) and intravenous immunoglobulin 10 g od for 7 days. The patient didn't receive anti-infective nor blood transfusion therapy.

Case progression and outcome

The patient was discharged after 3 weeks with oral prednisolone 40 mg qd and rivaroxaban 15 mg twice daily (bid). At 3-month follow up, reinspection of CTPA revealed disappearance of thrombosis (Fig 2b). At the recent follow-up, 12 months after the initial presentation, she required 5 mg od of prednisolone and 20 mg od of rivaroxaban to keep her haemoglobin (Hb) over 10 g/dL and had no thromboembolic episodes.

Discussion

Autoimmune haemolytic anaemia (AIHA) is a rare and heterogeneous disorders characterised by the destruction of red blood cells through warm or cold autoantibodies.2 The overall estimated incidence in adults is 0.8–3 per 100,000/year, a prevalence of 17:100,000 and a mortality rate of 3–4%.3,4 AIHA is the higher risk for thromboembolism due to hypercoagulability.2 AIHA occur in systemic lupus erythematosus (SLE), chronic lymphocytic leukaemia (CLL), infection, drug exposure and other mixed disorders.2,5,6 As early as 1967, Allgood et al reported that pulmonary embolism (PE) was the most common cause of death in AIHA, and revealed the association between PE and AIHA.7 Patients with AIHA have 2.6-fold higher risk of venous thromboembolism (VTE) compared with non-AIHA.8 In two large studies, the prevalence of thromboembolism in AIHA patients was recorded up to 15%.4,9 Anticoagulant prophylaxis can effectively reduce the occurrence of a thromboembolic episode in acute exacerbation of AIHA (4.7% vs 33.3%).10 The reasons for patients with AIHA were at an increased risk of VTE remain unclear, which may include the increased expression of phosphatidylserine, microparticles and cytokine-induced monocytes or endothelial tissue factors.8,11 Thromboembolic episodes are relatively common during active phases of the disease, but also occur during disease maintenance therapy.12 High leucocyte count and severe anaemia were associated with VTE.9 PE is a life-threatening complication of AIHA. Clinical manifestations of PE include sudden dyspnoea, hypoxaemia, and chest pain, which can easily be masked by severe anaemia caused by AIHA, leading to delayed diagnosis.13 Therefore, close attention as well as timely treatment plays a crucial role.

The causes of AIHA and PE are complex and varied, which need comprehensive evaluation in patients with PE at the first occurrence.1,2 In our case, considering that the patient had suffered recurrent infection without sufficiently effective treatment and haemoglobin gradually decreased in the past year, which strongly suggested that the prodromal infection induced AIHA. Previous literature reported that infection associated AIHA is not rare, accounting for 14% of all patients.11 Drug-related AIHA was excluded because the anaemia did not worsen after taking drugs such as moxifloxacin.

The first-line therapy for AIHA is glucocorticoids and approximately 80% of patients would respond to the therapy. There are no studies in comparing tapering regimens, where long duration and slow reduction are recommended. No response to steroids after 21 days or relapse during/after a steroid wean is an indication for the second-line therapy.2,3 This patient was administered with rivaroxaban sequent to LMWH, although there was insufficient evidence-based practice in the alternative of novel oral anticoagulants to vitamin K antagonists. Direct oral anticoagulants (DOACs) are not recommended in antiphospholipid syndrome (APS)-induced VTE.14 Notably, numbers of AIHA patients complicated with thromboembolism were reported with positive antiphospholipid antibodies.11 The thrombotic risk is reported to not correlate with traditional risk factors during AIHA.13 Vitamin K antagonists reduce functional coagulation factors in the extrinsic and intrinsic pathways of coagulation, which showed a stronger anticoagulant effect.15 Thus, it is uncertain that DOACs may be a perfect substitute to warfarin in VTE, especially attributed to thrombophilia or autoimmune diseases. In our case, DOACs are safe and effective for this patient, which providing a clinical evidence for anticoagulant therapy of AIHA-induced PE. Given the higher risk of thrombosis, long-term anticoagulation and follow-up should be recommended.12

Key points

  • AIHA is a hypercoagulable disorder, requiring vigilance against the complication of deep vein thrombosis.

  • Consider a wide range of differentials when patients present with PE attributed to AIHA.

  • No guidelines to recommend anticoagulant therapy for AIHA induced PE. DOACs may be effective and safe in APS-negative AIHA.

Supplementary material

Additional supplementary material may be found in the online version of this article at www.rcpjournals.org/clinmedicine:

S1 – Dynamic changes of laboratory results and process of diagnosis and treatment from the initial infection to follow-up.

Acknowledgements

Written informed consent was obtained from the patient to publish the clinical details and images in this article.

  • © Royal College of Physicians 2021. All rights reserved.

References

  1. ↵
    1. Konstantinides SV
    , Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020;41:543–603.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Jäger U
    , Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev 2020; 41:100648.
    OpenUrlPubMed
  3. ↵
    1. Hill QA
    , Stamps R, Massey E, et al. The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol 2017;176:395–411.
    OpenUrlPubMed
  4. ↵
    1. Barcellini W
    , Zaninoni A, Fattizzo B, et al. Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers. Am J Hematol 2018;93:e243–6.
    OpenUrl
  5. ↵
    1. Newman K
    , Owlia MB, El-Hemaidi I, Akhtari M. Management of immune cytopenias in patients with systemic lupus erythematosus - Old and new. Autoimmunity Reviews 2013;12:784–91.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Hodgson K
    , Ferrer G, Pereira A, Moreno C, Montserrat E. Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment. Br J Haematol 2011;154:14–22.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Allgood JW
    , Chaplin H Jr.. Idiopathic acquired autoimmune hemolytic anemia. A review of forty-seven cases treated from 1955 through 1965. Am J Med 1967;43:254–73.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Ungprasert P
    , Tanratana P, Srivali N. Autoimmune hemolytic anemia and venous thromboembolism: A systematic review and meta- analysis. Thromb Res 2015;136:1013–7.
    OpenUrl
  9. ↵
    1. Barcellini W
    , Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood 2014;124:2930–6.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Hendrick AM
    . Auto-immune haemolytic anaemia–a high-risk disorder for thromboembolism? Hematology 2003;8:53–6.
    OpenUrlCrossRef
  11. ↵
    1. Hoffman PC
    . Immune hemolytic anemia–selected topics. Hematology Am Soc Hematol Educ Program 2009:80–6.
  12. ↵
    1. Audia S
    , Bach B, Samson M, et al. Venous thromboembolic events during warm autoimmune hemolytic anemia. PLoS One 2018;13:e0207218.
    OpenUrl
  13. ↵
    1. Lecouffe-Desprets M
    , Néel A, Graveleau J, et al. Venous thromboembolism related to warm autoimmune hemolytic anemia: a case-control study. Autoimmunity Reviews 2015;14:1023–8.
    OpenUrl
  14. ↵
    1. Pengo V
    , Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018;132:1365–71.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Cohen H
    , Hunt BJ, Efthymiou M, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematology 2016;3:e426–36.
    OpenUrl
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Recurrent infection-induced autoimmune haemolytic anaemia complicated by pulmonary embolism: a case report and literature review
Shu Fang, Fan Yang
Clinical Medicine May 2021, 21 (3) e306-e308; DOI: 10.7861/clinmed.2021-0112

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Recurrent infection-induced autoimmune haemolytic anaemia complicated by pulmonary embolism: a case report and literature review
Shu Fang, Fan Yang
Clinical Medicine May 2021, 21 (3) e306-e308; DOI: 10.7861/clinmed.2021-0112
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ABSTRACT
    • Case presentation
    • Initial management
    • Case progression and outcome
    • Discussion
    • Key points
    • Supplementary material
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Acute intermittent porphyria: is oseltamivir safe in these patients?
  • Great balls of fire! The basal ganglia on fire
  • A case of unilateral pulmonary oedema associated with severe acute mitral regurgitation
Show more Acute medical care

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians